Tesamorelin Safe Package Fast Delivery Tesamorelin Intramuscular Injection
Tesamorelin, (formerly known as TH9507), is a type of peptide called a growth hormone-releasing factor (GHRF). GHRF causes growth hormone to be created and spread in the body, which helps increase metabolism, reduce belly fat, improve body shape, and use of energy.
Tesamorelin (formerly known as TH9507) is a synthetic growth hormone-releasing factor that stimulates the pituitary gland in the brain to secrete growth hormone; this indirect approach appears to maintain more stable, natural levels, like CJC-1295 DAC,. Clinical trials have shown that tesamorelin significantly reduces abdominal fat with fewer side effects than human growth hormone itself, although abdominal fat may return after the Tesamorlein is discontinued (depending upon the individual). Tesamorelin has been shown to reduce lipodystrophy in HIV-infected individuals as well as similarly reducing abdominal fat in NON-HIV-Infected individuals.
Product Name: Tesamorelin
Molecular Formula: C221H366N72O67S
Molecular Weight: 5135.77794
PubChem: CID 44201342
Synonyms: Hex-hGRF, ThGRF(1-44), TH-9507, (Hexenoyl trans-3)-hGRF(1-44)-NH2
Sequence (Three-Letter Code): trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
This medication is a synthetic GHRF. It stimulates the production of growth hormones by binding to receptors on anterior pituitary cells. These growth hormones affect metabolism and body shape. Tesamorelin targets fat accumulation in the abdominal area specifically. As this drug releases growth hormones, patients with active cancer should not take it.
The recommended dosage of tesamorelin is one daily 2-milligram subcutaneous injection. The medication is usually injected into the abdomen. The injection site should be rotated, avoiding scars, the navel, and bruises.
Prior to FDA approval, clinical studies were conducted on patients with HIV who had some fat accumulation and whose antiviral therapy was stable. Three studies of 816 patients showed that a daily treatment reduced abdominal fat after 26 weeks. Most patients experienced a reduction of approximately 18 percent. Abdominal fat began to accumulate again once the patients stopped treatment.
Tesamorelin has not shown evidence of drug interaction with any of the HIV antiretroviral drugs. Common side effects include mild joint aches and stiffness, mild swelling, and stiffness in the hands and feet. These problems usually abate with some gentle exercises that loosen the joints. Redness and tenderness at the injection site have also been observed but usually clear quickly. This medication has caused diabetic symptoms in some patients, and it is possible to develop antibodies that render tesamorelin less effective over time.
Patients should be forthcoming with their doctors about any medications, vitamins, and supplements they are taking prior to starting treatment. Diabetic patients will likely be monitored closely while taking this medication. Pregnant women or women who become pregnant while using tesamorelin should be informed of the drug’s potentially hazardous effects on unborn children.
HGH 176-191 2mg/vial
PEG MGF 2mg/vial
CJC-1295 with DAC 2mg/vial
CJC-1295 without DAC 2mg/vial
Pentadecapeptide BPC 157 2mg/vial
For more details Plz contact me by email@example.com